A Multicenter, Double-Blind, Randomized, Placebo Controlled Study of the Monophasic Oral Contraceptive YAZ (20 µg Ethinylestradiol, 3 mg Drospirenone) in the Treatment of Chinese Patients With Premenstrual Dysphoric Disorder (PMDD).

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo Controlled Study of the Monophasic Oral Contraceptive YAZ (20 µg Ethinylestradiol, 3 mg Drospirenone) in the Treatment of Chinese Patients With Premenstrual Dysphoric Disorder (PMDD).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2014

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary)
  • Indications Premenstrual dysphoric disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 02 May 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 02 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top